Ligand control of in vivo interaction between ecdysteroid receptor and Ultraspiracle ligand binding domain by Henrich, Vincent C. & NC DOCKS at The University of North Carolina at Greensboro
Biochem. J. (2004) 378, 779–784 (Printed in Great Britain) 779
Ligand control of interaction in vivo between ecdysteroid receptor and
ultraspiracle ligand-binding domain
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Ecdysteroids (Ecs) enhance the formation of Ec receptor–ultra-
spiracle protein (EcR–USP) heterodimers which regulate gene
transcription. To study EcR–USP heterodimerization, fusion pro-
teins were constructed from the LBDs (ligand-binding domains)
of Drosophila EcR or USP and the activation or DNA-binding
region of GAL4 respectively. Reporter gene (lacZ) activation
was fully dependent on the co-expression of the two fusion pro-
teins and thus constitutes a reliable measure for the interaction
in vivo between the two LBDs in the yeast cell. To identify struc-
tures involved in heterodimerization, a total of 27 point mutations
were generated in the EcR and USP LBDs at selected sites. Hetero-
dimerization and its inducibility by ligand were mainly affected
by mutations in the dimerization interface and in the ligand-
binding pocket of EcR respectively. However, also mutations not
located in these structures or even in the LBD of USP influenced
ligand-dependent heterodimerization. Together with previously
reported ligand-binding studies, the existence of such local, intra-
and inter-molecular mutation effects suggest that ligand-induced
dimerization results from a synergistic interaction between ligand-
binding and heterodimerization functions in EcR LBD, and that
it depends on global features of the LBDs of EcR and USP and
on their mutual surface compatibility.
Key words: Drosophila melanogaster, ecdysone, heterodimeriza-
tion, nuclear hormone receptor, site-directed mutagenesis, yeast
two-hybrid analysis.
INTRODUCTION
Ecdysteroids (Ecs) govern insect development [1,2], mainly by
means of the so-called EcR (Ec receptor) complex, a heterodimer
[3] between EcR [4] and USP (Ultraspiracle protein) [5–7], which
acts through regulation of gene activity. It has been shown by
experiments in vivo and in vitro that heterodimerization of EcR
with USP is ligand-controlled ([8,9], and references therein).
Ligand-induced dimerization between EcR and USP may thus
constitute an important step in the Ec-controlled process, leading
to the functional EcR complex [9].
The present study shows for the first time some general
principles underlying Ec-controlled interactions between the
LBDs (ligand-binding domains) of EcR and USP at a molecular
level and under conditions occurring in a living cell. Twenty-seven
site-directed mutations of selected usually conserved amino acid
residues located in various functionally different structures of the
EcR and USP LBDs were tested for their effects on spontaneous
and ligand-induced heterodimerization by the yeast two-hybrid
system. This in vivo system is devoid of interfering nuclear
receptors, co-activators and co-repressors [10], and monitors even
weak and ephemeral interactions under conditions which exclude
artefacts in vitro (see e.g. [11,14], for critical role of buffer
composition) and ensure optimal control of EcR–USP interaction.
Our results demonstrate that the mutations mainly affected the
targeted function, but also influenced the behaviour of distant
structures, even of the non-mutagenized heterodimerization
partner. These intra- and inter-molecular effects suggest that the
various regions of the LBDs are functionally linked and regulated
across the entire trinary complex. They imply that ligand binding
Abbreviations used: Ec, ecdysteroid; EcR, Ec receptor; USP, ultraspiracle protein; LBD, ligand-binding domain; DIF, dimerization interface; LBP,
ligand-binding pocket; MT, ‘mouse-trap’; RXR, 9-cis-retinoic acid receptor; RAR, retinoic acid receptor; Ef lig, ligand effect; M.U., Miller units.
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causes not only local, but also global transitions of the EcR LBD
to control the interaction with the USP LBD.
EXPERIMENTAL
Yeast strains and two-hybrid assay
Yeast strain, growth and hormone treatment were the same as
described previously [9]. For induction experiments, the cultures
were split; one half received the potent Ec muristerone A, and the
other half solvent only. The muristerone A concentration in
the culture medium was always 25 µM, which is much higher
than the effective intracellular concentrations, but still far from
saturating the heterodimerization reaction (see [9]).
Expression plasmids and site-directed mutagenesis of
EcR and USP LBDs
The wild-type two-hybrid components are as described pre-
viously [9]. Selected amino acid residues in the LBD of EcR were
mutated using the QuikChange® Mutagenesis Kit (Stratagene,
La Jolla, CA, U.S.A.), with plasmids pACT2-EcR(375-652)
or pST-EcR(2-878) [12] as a template. The StuI–BSiWI frag-
ment of wild-type EcR in pACT2-EcR(375-652) was replaced
by the corresponding mutated fragment generated by PCR and
the primers listed in the Supplementary Table 1 (http://www.
BiochemJ.org/bj/378/bj3780779add.htm). Similarly, site-di-
rected mutations were introduced into the LBD of USP using
pSCT-dUSP [13] as a template and by replacing the ClaI–BssHII
fragment in pAS2-1-USP(172-508). The mutations at the given
c© 2004 Biochemical Society
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Figure 1 For legend see facing page
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sites of the EcR [4] and USP sequence [6], the designation of the
respective plasmid, and the oligonucleotide employed for each are
listed in Supplementary Table 1 (http://www.BiochemJ.org/bj/
378/bj3780779add.htm). Sequencing of inserts (by Microsynth,
Gachnang, Switzerland or GENterprise, Mainz, Germany) to
check for the absence of random mutations revealed a Ser330 →
Asn (S330N) mutation in the USP C329A construct [therefore
named USP(C329A + S330N)]. With constructs exhibiting very
low expression, the entire plasmid was sequenced. Mutated
EcR and USP LBD-fusion proteins were expressed individually
in yeast cells and checked for expression level, expected size,
ligand binding and DNA binding by Western blot analysis,
[3H]ponasterone A-binding assay and electrophoretic mobility-
shift assay respectively (see [9,14,15]). Correlation analyses
showed that the upto 2-fold variation in expression levels
observed with the different mutants [14] cannot be responsible
for the effects described in the present work.
Choice of mutations
LBDs of mammalian RAR (retinoic acid receptor) and RXR (9-
cis-retinoic acid receptor) are the only EcR-/USP-related nuclear
receptor LBDs [16,17] for which a heterodimeric crystallographic
structure is available to date [18]. This three-dimensional infor-
mation, together with sequence alignments (Supplementary Fig-
ure, http://www.BiochemJ.org/bj/378/bj3780779add.htm), gave a
general idea of the overall structure of the EcR–USP heterodimer
and allowed the identification of respective regions as the DIF
(dimerization interface), LBP (ligand-binding pocket) or MT
(‘mouse-trap’) (the term mouse-trap has been coined by [19] and
designates those LBD structures which ensure the entrapping of
the ligand in the LBP; these structures comprise the movable
‘lid’ composed of helices 11 and 12 and their flexible interhelical
‘joints’, as wells as the ‘lock’ in helix 4 which holds the ‘lid’
closed). Figure 1(A) shows the approximate spacial relationship
of DIF, LBP and MT. To produce DIF, LBP or MT mutations,
sites in EcR LBD were selected that correspond to sites in RAR
and/or RXR LBD which were shown to contact with either the
dimerization partner or the ligand, or relate to the ‘mouse-trap’
mechanism [see Supplementary material (http://www.BiochemJ.
org/bj/378/bj3780779add.htm) and references therein], unless
stated otherwise. Two mutations were subsequently reclassified
because of inconsistencies with or among the various published
homology models for the EcR LBD [see Supplementary mate-
rial (http://www.BiochemJ.org/bj/378/bj3780779add.htm)]. USP
mutations were made in the cavity that corresponds to the
ligand binding pocket in other receptors (Figure 1A). The current
debates regarding possible ligands for and the natural conform-
ation of USP LBD (compare with [17]) are not addressed in the
present work nor do they affect its basic outcome and overall
interpretation. Many selected residues were mutated to the mode-
rately hydrophobic, small amino acid, alanine, which has a
minimal impact on the protein structure, in order to eliminate
Figure 1 Site-directed mutations in the LBD of Drosophila EcR and USP and their effects
(A) Approximate location of mutations projected into the canonical three-dimensional model for nuclear receptor LBDs [20], which is based on crystallographic measurements of the all-trans-RAR
(yellow) [19] and the RXR LBD (pink) [22,27] and of their heterodimeric complex [18]. H1–H12, α-helices 1 to 12. B1 and B2: β-strands 1 and 2. Stippled regions, most variable and most uncertain
structures. Colour of dots: red, DIF mutations in EcR LBD; green, LBP mutations in EcR LBD; blue, MT mutations in EcR LBD; grey, controls to EcR mutations and mutations at sites of unknown
or uncertain functions (Supplementary Figure, http://www.BiochemJ.org/bj/378/bj3780779add.htm); turquoise, USP mutations. Letters in dots correspond to mutations listed in (B). (B) Impact of
mutations on spontaneous and ligand-induced heterodimerization between EcR and USP LBDs fused to GAL4-activation and DNA-binding region, respectively, unless stated otherwise. 1) Colour code
as in (A); 2) M.U.: Miller Units, a measure for reporter β-galactosidase activity in the two-hybrid assay; 3) ligand effect (Ef lig) defined as averaged ratios of induced/spontaneous heterodimerization; 4)
main impact of mutation calculated from the fold increase or decrease of spontaneous heterodimerization and Ef lig in comparison to wild-type. 5) Fusion protein with GAL4 DNA binding or activation
domain combined with reciprocal GAL4 domain alone (for respective constructs, see [9]); 6) Bkgd.: Background > 0.04 M.U.. *: P=Bkgd. or P=1 for Ef lig)  0.05. #: P=wt  0.05. For detailed
statistical information, see Supplementary Table 2 (http://www.BiochemJ.org/bj/378/bj3780779add.htm).
the function of the native residue. Additional mutations were
produced to change hydrophobicity and/or charge of EcR LBD.
Some mutations were patterned according to other specific criteria
(see below).
RESULTS AND DISCUSSION
In order to identify structures involved in ligand-induced
heterodimerization between the LBDs of EcR and USP, 27
individual site-directed mutations were generated and analysed
by the yeast two-hybrid system for effects on β-galactosidase
activity, used as a reporter for this interaction, in the absence
or presence of muristerone A. Control experiments revealed
that activation of the respective reporter gene (lacZ) was fully
dependent on the co-expression of the two fusion proteins between
EcR or USP LBD and GAL4 activation or DNA-binding domain
respectively (Figure 1B, [9] and results not shown). This conforms
with the previously obtained evidence that yeast cells lack co-
activators, co-repressors or other general transcription factors
which could interact with EcR or USP LBDs ([10], see also
combination experiments below) and thereby jeopardize the
yeast two-hybrid assay. The potent Ec muristerone A promoted
heterodimerization between the fusion proteins of EcR and
USP LBDs with all mutations investigated, albeit to different
degrees varying over a large range from 0.13 (EcR S531T) to 67
(EcR T619K) Miller Units (M.U.; a measure for β-galactosidase
activity; Figure 1B, column 4). The majority of mutations re-
duced the heterodimerization induced by muristerone A compared
with the wild-type, although a remarkable minority enhanced it.
Mutations increased ligand-induced heterodimerization
compared with the wild-type because they enhanced spontaneous
heterodimerization (EcR mutations K497A, K497E, S553A and
I617E; see Figure 1A and Table 1), because they enhanced the
ligand effect (mutations: EcR, N626A and T619K; USP, L322G
and I323A) or because of both (EcR mutations E583L and
T619A). The first group are called ‘hyperdimerizers’, as they
achieve a score for spontaneous heterodimerization significantly
greater than wild-type (>0.41 M.U.); the second group are
called ‘superinducers’, as they confer to the two-hybrid assay
an inducibility by 25 µM muristerone A that is significantly
greater than wild-type (Ef lig > 20, where Ef lig is the ligand
effect, quotient induced/spontaneous heterodimerization); and
the third group will be called either one. Mutations reducing
ligand-induced heterodimerization below the wild-type level may
be grouped in an analogous manner. The ligand effect showed
no consistent negative correlation with the extent of spontaneous
heterodimerization, but a strong positive correlation with ligand
binding to EcR LBD for all mutations analysed (Figure 2).
These findings suggest a relation between ligand binding and
dimerization, and indicate the existence of a functional interaction
between the presumed sites of action, i.e., the LBP and DIF
in EcR LBD. This interaction must be positive, since ligand
c© 2004 Biochemical Society
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Table 1 General enhancement of spontaneous and ligand-induced hetero-
dimerization by a polar exchange
In the first step, the natural residue was replaced by alanine to exclude effects due to extinction
of specific functions by natural residues. The alanine residues were then substituted with the
following polar amino acids: Lys497 and Ile617, Glu; Ser553, Asp; Asp572, Ser; Thr619 and Asn626,




Residue WT Alanine Polar WT Alanine Polar
Lys497 0.41 5.6 23 7.9 9 46
Ser553 0.41 0.93 3.7 7.9 18 51
Asp572 0.41 0.13 1.0 7.9 0.77 19
Ile617 0.41 1.0 4.0 7.9 4.0 19
Thr619 0.41 0.9 1.3 7.9 26 67
Asn626 0.41 0.4 0.9 n.d.
Figure 2 Correlation between ligand binding (B) and ligand effect (Ef lig)
Double logarithmic plot of ligand binding to mutated EcR in the absence of USP LBD (abscissa,
data from [14]) and ligand effect (Ef lig) on heterodimerization between mutated EcR and wild-
type USP LBD (ordinate, this work, only values with 95 %-confidence limits <+− 50 % of Ef lig
are shown). Ligand binding was determined by specific [3H]ponasterone A binding [9,14]. ,
Wild-type EcR LBD; its ligand binding value is set to unity. The EcR mutants are from left to right:
M504R, K497A, E648K, R511Q and K497E (double dot), I617A, E476A, E647R, I463T, N626A,
A612V, wild-type EcR, T619A and T619K. For localization and classification of mutations, see
Figure 1. r = 0.97 (Pr=0  0.001). For statistical information, see Supplementary Table 2
(http://www.BiochemJ.org/bj/378/bj3780779add.htm). Note that the positive correlation shows
that Ef lig ∼ B. As Ef lig = Di/Ds (Di, ligand-induced dimerization; Ds, spontaneous dimerization),
it follows that B ∼ Di/Ds, which can be transformed mathematically into Di ∼ Ds × B. This
theoretical consideration is supported by the positive correlation (inset, double logarithmic
plot) between the measured Di values (Figure 1B and Table 1) and the products (Ds × B) of
measured Ds (Figure 1B and Table 1) and published B values [14]. r = 0.72 (Pr = 0 < 0.01).
The multiplication function signifies cooperativity (synergism) between dimerization and ligand
binding.
binding enhances heterodimerization and vice versa (present
study and [9]). Biochemical studies performed under saturating
conditions (see below) suggested the action of dimerization on
ligand binding to be ‘complementary’ or ‘compensatory’ [14].
However, correlation analyses of ligand binding to EcR LBD
and spontaneous or ligand-induced heterodimerization (Figure 2)
indicate that the interaction between the dimerization and the
ligand-binding function is in fact synergistic (Figure 2, inset).
Consideration of the effect of mutations targeted to the two pre-
sumably key players, the DIF and the LBP, shows that there
is no doubt that both structures are involved in ligand-induced
heterodimerization (Figure 1). The main impact of DIF mutations
(red colour in Figure 1) was on spontaneous heterodimerization,
whereas that of LBP mutations (green) was on the ligand effect
(ligand binding, [14]). The so-called MT, (see [19] and the Experi-
mental section for explanation) plays a pivotal role in ligand-
controlled effects on LBD, since it is known to undergo a con-
spicuous conformational change upon ligand binding ([20,20a]).
MT mutations (blue colour in Figure 1) dramatically affected
spontaneous heterodimerization and/or the ligand effect. For
example, E497A was the most efficient ‘hyperdimerizer’, whereas
N626A was the second most potent ‘superinducer’ among the non-
polar EcR mutations. These findings substantiate the postulated
role of the MT as a master switch for allosteric effects induced by
ligand. However, parts of the LBD other than the MT could also be
crucial for allosteric transitions occurring during ligand-induced
heterodimerization. The mutation I617A depressed ligand action
as an exception among non-polar ‘hyperdimerizers’, whereas
D572A and E583L had an equal impact on ligand effect and
heterodimerization (Figure 1B). Although all three sites are
located in important structures (helices 10, 7 and 9 respectively) of
the DIF, these sites might also contribute to protein architecture.
The EcR mutation E476A was constructed to serve as a
control to the DIF, LBP and MT mutations. Its impact on spon-
taneous heterodimerization, but particularly on the ligand effect
(Figure 1B), is unexpected, because this site neither contacts USP
LBD or the ligand nor is it involved in the MT or any other
structure that undergoes a large ligand-induced conformational
change [Figure 1A and Supplementary Figure (http://www.
BiochemJ.org/bj/378/bj3780779add.htm)]. This led us to assume
that the E476A mutation and possibly many other mutations
cause global alterations of the LBD. Investigations on isolated and
purified LBDs of the thyroid receptor or of RXR demonstrate that
global alterations of the LBD also occur upon ligand binding, i.e.,
in addition to the triggering of the MT. These ligand-inducible
global effects are: (i) reduction of surface hydrophobicity,
(ii) compaction and (iii) stabilization of the overall structure
of the LBD [21–23]. The ligand is obviously required for a
dynamic stabilization of the intermolecular interaction between a
helix 1-truncated thyroid receptor LBD and a helix 1-containing
peptide [21]. Collectively, these observations gave rise to the
idea that ligand-inducible global effects may positively affect
the interaction of EcR with the USP LBD. To test the possible
influence of surface hydrophobicity, sites were investigated which
do not belong to LBD core structures. A first round of site-directed
mutations indicated (Figure 1B) that a change in hydrophobicity
may indeed correlate with heterodimerization in some cases
(E476A, S531T, D572A and K613A), but not in others. Thus
to reduce the possibility of an interference by effects other
than surface hydrophobicity, we chose seven sites that had been
already exchanged by alanine and introduced a subsequent sub-
stitution by a polar residue. This allowed a clear comparison
between a hydrophobic and polar situation. The data presented
in Table 1 demonstrate that in all the cases investigated the
polar exchange caused an increase in spontaneous and ligand-
induced heterodimerization when compared with the respective
alanine residue. Although it is not yet known how a change in
hydrophobicity affects EcR–USP dimerization, the possibility
that Ecs, such as thyroids, might reduce their receptors’ hydro-
phobicity and thereby promote intermolecular interactions is
obvious and deserves further investigations.
c© 2004 Biochemical Society
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Figure 3 Effects of combining site-directed mutations in EcR and USP LBDs
on spontaneous heterodimerization (A) and ligand effect Ef lig (see Figure 1)
on heterodimerization (B)
The wild-type (wt) or mutated (overlapping boxes) EcR LBD indicated in the top line was combined
with the wild-type or mutated USP LBD indicated underneath respectively. Closed columns,
wild-type × wild-type combinations; Dotted columns, mutated × mutated combinations. *,
# and M.U., see Figure 1; For detailed statistical information, see Supplementary Table 2
(http://www.BiochemJ.org/bj/378/bj3780779add.htm).
Mutations inside the USP LBD either reduced (L281Y and
C329A + S330N) or enhanced (I323A and L322G) Ec-induced
heterodimerization (turquoise colour in Figure 1). These ligand
effects are not due to a direct interaction between muristerone
A and the LBP of USP, since Ecs neither bind to [9,14,15]
nor stimulate the dimerization [9] or transactivation ability (Fig-
ure 1B and results not shown; [11]) of the USP LBD itself, whether
or not the latter has been mutated. A ‘transmolecular effect’ [24]
of the USP mutations on the ability of the EcR LBP to bind
ligand can practically be ruled out as well. This would require
a strong interaction of the USP LBD with that of EcR prior to
ligand binding, which is not supported by our results (Figures 1B
and 3). We prefer to interpret the effects of the USP mutations
according to the so-called ‘DIF compatibility model’ [25]. This
model postulates that the intermolecular effect of USP mutations
is due to an indirect alteration of the USP DIF, thus decreasing or
increasing the affinity of the USP LBD for a given, e.g. ligand-
dependent, conformation of the EcR LBD. The combination
of the ‘superinducible’ mutants EcR T619A and USP I323A
potentiated the ligand effect on heterodimerization, suggesting
that USP I323A has an exceptionally high affinity to the holo-
conformation of EcR T619A. In contrast, the combination of the
‘hyperdimerizer’ EcR K497A and ‘superinducer’ USP I323A not
only curtailed the ‘hyperdimerization’ activity of EcR K497A, but
also antagonized the ‘superinducer’ activity of USP I323A (Fig-
ure 3B), which is explained by a very low compatibility between
these two mutants [25], rather than by an interaction with hypo-
thetical yeast proteins or transcription factors (compare with
[14]).
‘Hyperdimerization’ and ‘superinduction’, as observed in the
present work, only occur under conditions which do not saturate
the heterodimerization reaction. At saturation, each EcR LBD
can bind no more than possibly one ligand molecule and one
USP LBD. Therefore, differences in ligand-induced hetero-
dimerization, e.g. between wild-type EcR or USP and USP I323A
or EcR K497A, disappear or become reversed respectively at
very high muristerone A concentrations (W.W. Hitchcok and
V.C. Henrich, unpublished work). Most assays in vitro for
heterodimerization are performed at saturating conditions and
thus yield at best results corresponding to those obtained with
wild-type EcR and USP LBDs (compare Figure 3B in [9] and
Figure 4C in [14]). It is only ligand binding to EcR LBD alone (a
very weak binding being far away from the point of saturation)
which allows values that exceed those achieved by wild-type LBD
at the same ligand concentration to be seen [14]. The determined
ligand-binding values for the set of EcR LBD mutants analysed
generally paralleled the ligand effect on heterodimerization in
the yeast cell (Figure 2). In the living organism Ecs act under
conditions which ensure optimal control rather than maximal
effect [8]. Therefore experiments carried out at non-saturating
conditions in vivo, as in the present study, are especially adequate
to characterize the situation in the living insect cell.
From our mutational analyses, one may deduce the following
general points regarding EcR–USP interaction. (i) The capability
of a receptor to undergo ligand-induced heterodimerization relates
to both its basic ability to bind ligand and to bind its hetero-
dimerization partner, each independently of the other (present
study and see also [9,14] for a naturally resistent EcR form).
In the actual process of ligand-induced heterodimerization these
two functions then interact synergistically. (ii) The LBP, DIF
and MT play a crucial, although not exclusive, role in this inter-
action. (iii) Global effects, such as a decrease in the hydro-
phobicity of the LBD of a receptor, facilitate intermolecular
interactions; it is known that ligands can elicit such global effects.
(iv) Ligand binding to a receptor influences its compatibility
with cognate dimerization partners which, conversely, ‘sense’
to a varying degree whether the receptor partner is liganded.
The relevance of our findings is supported by other studies
in vivo: the USP mutation I323A, for example, potentiates the
effect of Ec in a transgenic mouse cell line (M.O. Imhof, personal
communication), whereas the mutations S531T and A612V in
EcR (which are reconstructions of published in vivo mutations
[26]) impair survival of Drosophila larvae [26] at the same
proportion as they do in our assay system. Thus our studies using
site-directed mutagenesis, and subsequently analysis in vivo,
yielded useful information to characterize the regulation of the
EcR–USP interaction under physiological conditions. A detailed
mechanistic interpretation of the effects observed is yet not
feasible. It will have to await the solution of the molecular
structure of the natural EcR–USP heterodimer in the liganded
and non-liganded configuration. For both further investigations
in physiological/developmental or biochemical/structural direc-
tions, this group of 27 mutations we have provided and
characterized is undoubtedly of great pratical value (cf. [14]).
Note added in proof (received 19 November 2003)
After the acceptance of the present paper for publication, an
article by Billas and co-workers [27a] was published on the crystal
structure of the heterodimer between the LBDs of EcR and USP
in their holoconformation from the moth Heliothis virescens.
Although the measured EcR LBD structure, exhibiting the
canonical folding, deviates from any homology model published
previously, the three-dimensional data in the study by Billas et al.
[27a] do not affect the rough classification of our mutations nor
the principal conclusions drawn from our findings in the present
paper. The high structural adaptability and flexibility discovered
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by these authors [27a] support our postulation of extensive and
strong intra- and inter-molecular interactions in ligand-controlled
EcR–USP heterodimerization.
Note added in proof (received 5 December 2003)
Recent experiments (V. C. Henrich, unpublished work) indicate
that mutation K497E conveys a high level of constitutive activity
to a cellular mammalian gene induction system when introduced
into a specific full-length EcR form. This is consistent with the
high spontaneous heterodimerization activity of that mutation
which we found in our yeast two-hybrid assay.
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13 Vögtli, M., Imhof, M. O., Brown, N. E., Rauch, P., Spindler-Barth, M., Lezzi, M.
and Henrich, V. C. (1999) Functional characterization of two Ultraspiracle forms
(CtUSP-1 and CtUSP-2) from Chironomus tentans. Insect Biochem. Mol. Biol.
29, 931–942
14 Grebe, M., Przibilla, S., Henrich, V. C. and Spindler-Barth, M. (2003) Characterization of
the ligand-binding domain of the ecdysteroid receptor from Drosophila melanogaster.
Biol. Chem. 384, 105–116
15 Grebe, M. (2001) Charakterisierung des Ecdysteroidrezeptors als target für
arthropodenspezifische Insektizide. PhD Thesis, University of Düsseldorf (FRG),
pp. 1–122
16 Wurtz, J.-M., Guillot, B., Fagart, J., Moras, D., Tietjen, K. and Schindler, M. (2000) A
new model for 20-hydroxyecdysone and dibenzylhydrazine binding: a homology and
docking approach. Protein Sci. 9, 1073–1084
17 Sasorith, S., Billas, I. M. L., Iwema, T., Moras, D. and Wurtz, J.-M. (2002)
Structure-based analysis of the Ultraspiracle protein and docking studies with putative
ligands (11 pp). J. Insect Sci. 2.25 (http://insectscience.org/2.25/)
18 Bourguet, W., Vivat, V., Wurtz, J.-M., Chambon, P., Gronemeyer, H. and Moras D. (2000)
Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains.
Mol. Cell 5, 289–298
19 Renaud, J.-P., Rochel, N., Ruff, M., Vivat, V., Chambon, P., Gronemeyer, H. and
Moras, D. (1995) Crystal structure of the RAR-γ ligand-binding domain bound to
all-trans retinoid acid. Nature (London) 378, 681–689
20 Wurtz, J.-M., Bourguet, W., Renaud, J.-P., Vivat, V., Chambon, P., Moras, D. and
Gronemeyer, H. (1995) A canonical structure for the ligand-binding domain of nuclear
receptors. Nat. Struct. Biol. 3, 87–94
20a Wurtz, J.-M., Bourguet, W., Renaud, J.-P., Vivat, V., Chambon, P., Moras, D. and
Gronemeyer, H. (1995) Erratum. Nat. Struct. Biol. 3, 206
21 Pissois, P., Tzameli, I., Kushner, P. and Moore, D. D. (2000) Dynamic stabilization of
nuclear receptor ligand binding domains by hormone or corepressor binding. Mol. Cell
6, 245–263
22 Egea, P. F., Mitschler, A., Rochel, N., Ruff, M., Chambon, P. and Moras, D. (2000) Crystal
structure of the human RXRα ligand-binding domain bound to its natural ligand: 9-cis
retinoid acid. EMBO J.19, 2592–2601
23 Apriletti, J. W., Baxter, J. D., Lau, K. H. and West, B. L. (1995) Expression of the rat α1
thyroid hormone receptor ligand binding domain in Escherichia coli and the use of a
ligand-induced conformation change as a method for its purification to homogeneity.
Protein Expression Purif. 6, 363–370
24 Vivat, V., Zechel, C., Wurtz, J.-M., Bourguet, W., Kagechika, H., Umemiya, H., Shudo, K.,
Moras, D., Gronemeyer, H. and Chambon, P. (1997) A mutation mimicking ligand-
induced conformational change yields a constitutive RXR that senses allosteric effects
in heterodimers. EMBO J. 16, 5697–5709
25 Lezzi, M. (2002) Dimerization interface (DIF-) model for nuclear receptor interaction
(Abstracts from the XVth International Ecdysone Workshop). J. Insect Sci. 2.16
(http://insectscience.org/2.16/)
26 Bender, M., Imam, F. B., Talbot, W. S., Ganetzky, B. and Hogness, D. S. (1997)
Drosophila ecdysone receptor mutations reveal functional differences among receptor
isoforms. Cell (Cambridge, Mass.) 91, 777–788
27 Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H. and Moras D. (1995) Crystal
structure of the ligand-binding domain of the human nuclear receptor RXR-α. Nature
(London) 375, 377–382
27a Billas, I. M., Iwema, T., Garnier, J. M., Mitschler, A., Rochel, N. and Moras, D. (2003)
Structural adaptability in the ligand-binding pocket of the ecdysone hormone receptor.
Nature (London) 426, 91–96
Received 26 August 2003/10 October 2003; accepted 31 October 2003
Published as BJ Immediate Publication 31 October 2003, DOI 10.1042/ BJ20031302
c© 2004 Biochemical Society
